Septic shock and community-acquired pneumonia associated with etanercept therapy

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 4, 2008, Pages 193-197

  Nunez Cornejo C ^a   Borras Blasco J ^a   Gracia Perez, A ^a   Rosique Robles, J D ^a   Lopez Camps, V ^a   Castera E ^a   Abad, F J ^a  

^a HOSPITAL DE SAGUNTO   (Spain)

Author keywords

Adverse drug reaction; Etanercept; Pneumonia; Psoriatic arthritis; Septic shock; Streptococcus pneumoniae; Tumor necrosis factor

Indexed keywords

ACETYLCYSTEINE; AMIKACIN; AMIODARONE; CEFEPIME; CELECOXIB; CHONDROITIN SULFATE; CORTICOSTEROID; ENOXAPARIN; ETANERCEPT; LEVOFLOXACIN; PARACETAMOL;

AGED; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; CARDIOVERSION; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DETERIORATION; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FEVER; FLUID THERAPY; GENERAL PRACTITIONER; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LUNG INFILTRATE; MEDICAL ASSESSMENT; PATIENT CARE; PATIENT COUNSELING; PSORIATIC ARTHRITIS; RESPIRATORY TRACT INTUBATION; SEPTIC SHOCK; SHOCK; STREPTOCOCCUS PNEUMONIAE; TACHYCARDIA; TACHYPNEA; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST; URINALYSIS; WEAKNESS;

EID: 41849116698     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp46193     Document Type: Article

References (22)

1. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001; 76: 653-656.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295. 2275-2285.
3. Borrás-Blasco J, Nuñez-Cornejo C, Gracia-Perez A, Rosique-Robles JD, Castera MD, Viosca E et al. Parapharyngeal abscess in a patient receiving etanercept. Ann Pharmacother. 2007; 41: 341-344.
4. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005; 84: 291-302.
5. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21: 2286-2291.
6. Goffe B, Gather JC. Etanercept: an overview. J Am Acad Dennatol 2003; 49: 105-111.
7. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48: 2122-2127.
8. Johnson CJ, Reilly KM, Murria K. Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001; 35: 464-471.
9. Kohlhammer Y, Schwartz M, Raspe H, Schafer T. Risk factors for community acquired pneumonia (CAP). A systematic review. Dtsch Med Wochenschr. 2005; 130: 381-386.
10. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000; 34: 161-164.
11. Marcos MA, Jimenez de Anta MT, de la Bellacasa JP, Gonzalez J, Martinez E, Garcia E et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J. 2003; 21: 209-214.
12. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med. 1999; 130: 478-486.
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245.
14. Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum. 2003; 48: 1853-1857.
15. Noguera-Pons R, Borras-Blasco J, Romero-Crespo I, Anton-Torres R, Navarro-Ruiz A, Gonzalez-Fernandez JA. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. 2005; 39: 2131-2135.
16. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005; 25: 1181-1192.
17. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006; 355: 704-712.
18. Uthman I, Husari A, Touma Z, Kanj SS. Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept. Rheumatology (Oxford). 2005; 44: 1200-1201.
19. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48: 35-45.
20. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2006; 10: 1-258.
21. Zhou H, Buckwalter M, Boni J, Mayer P, Raible D, Wajdula J et al. Population-based pharmacokinetics of the soluble TNF-α etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004; 42: 267-276.
22. Zimmer C, Beiderlinden M, Peters J. Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin Rheumatol. 2006; 25: 430-432.